# US 2025/0325554 A1 · Methods and pharmaceutical compositions to treat respiratory depression in patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325554 A1
- Document ID: US20250325554A1
- Status: Published application
- Kind: A1
- Application number: 18/866,742
- Filed: 2023-05-18
- Published: 2025-10-23
- Earliest claimed: 2022-05-19
- Assignees: Enalare Therapeutics Inc.
- Applicants: Enalare Therapeutics Inc.
- Inventors: Joseph PERGOLIZZI; Robert B. RAFFA; Alfred SCHWEIKERT
- Web page: https://patentgrep.com/patent/US20250325554A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a method of treating respiratory depression in a patient after discontinuation of ventilator therapy comprising administering a respiratory stimulant to a patient in need thereof.

## Claims

### Claim 1

A method of treating respiratory depression in a patient after discontinuation of ventilator therapy comprising administering a respiratory stimulant to a patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ventilator therapy is to treat respiratory depression in a patient experiencing a bacterial or viral infection.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering hydroxychloroquine to the patient.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering an antibiotic to the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the antibiotic is azithromycin.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering an antiviral to the patient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antiviral is amantadine.

### Claim 8 (depends on 1)

The method of claim 1, wherein the respiratory depression after discontinuation of ventilator treatment is caused by demyelination, atelectasis, or a combination thereof.

### Claim 9 (depends on 1)

The method claim 1, wherein the ventilator therapy is to treat respiratory depression caused by administration of an active agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the active agent is to treat pain, cough or constipation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the agent is an opioid analgesic.

### Claim 12 (depends on 1)

The method of claim 1, wherein the respiratory stimulant triggers ventilation in the lungs.

### Claim 13 (depends on 12)

The method of claim 12, wherein the wherein the respiratory stimulant triggers ventilation in the lungs through a physiological mechanistic process.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mechanistic process is through the carotid bodies.

### Claim 15 (depends on 1)

The method of claim 1, wherein the respiratory stimulant is selected from the group consisting of Doxapram, Almitrine, ENA-001, and a pharmaceutically-acceptable salt thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the respiratory stimulant is at least one compound of formula (I):
wherein:
R1 and R2 are independently H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heteroaryl or substituted heteroaryl; or R1 and R2 combine as to form a biradical selected from the group consisting of 3-hydroxy-pentane-1,5-diyl, 6-hydroxy-cycloheptane-1,4-diyl, propane-1,3-diyl, butane-1,4-diyl and pentane-1,5-diyl;
R3 is H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —NR1R2, —C(O)OR1, acyl, or aryl;
R4 is H, alkyl, or substituted alkyl;
R5 is H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —OR1, —NR1R2, —C(O)OR1, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic; or R3 and R5 combine as to form a biradical selected from the group consisting of 3,6,9-trioxa-undecane-1,11-diyl and 3,6-dioxa-octane-1,8-diyl;
R6 is H, alkyl, substituted alkyl or alkenyl;
X is a bond, O or NR4; and, Y is N, CR6 or C; wherein:
if Y is N or CR6, then bond b1 is nil and: (i) Z is H, bond b2 is a single bond, and A is CH;
or, (ii) Z is nil, bond b2 is nil, and A is a single bond; and,
if Y is C, then bond b1 is a single bond, and: (i) Z is CH2, bond b2 is a single bond, and A is CH; or, (ii) Z is CH, bond b2 is a double bond, and A is C;
or a salt thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the active agents are administered simultaneously or sequentially.

### Claim 18 (depends on 1)

The method of claim 1, wherein at least two active agents are administered sequentially.

### Claim 19 (depends on 1)

The method of claim 1, wherein the active agents are administered by the same route of administration.

### Claim at position 20

20-32. (canceled)

### Claim 33

A pharmaceutical composition comprising an effective amount of a respiratory stimulant to treat respiratory depression in a patient after discontinuation of ventilator therapy.

### Claim at position 22

34-50. (canceled)
